About Aarti Pharmalabs Limited (APL) 

Aarti Pharmalabs Limited (APL) was established in 1984 as a wholly owned subsidiary of Aarti Industries Limited and was demerged into a separately listed entity in October 2022 (effective July 2021) . The company is an established manufacturer of generic Active Pharmaceutical Ingredients (APIs) and intermediates, the largest Indian manufacturer of Xanthine derivatives, and a leading small-molecule CDMO/CMO player . Its portfolio spans 200+ products supported by 3 state-of-the-art R&D centres and 6 manufacturing units, including 3 USFDA-approved facilities; the company serves 500+ global clients across 50+ export countries and employs 2,000+ people . APL holds 41 US DMFs and 22 CEPs and maintains accreditations including USFDA, EU GMP, EDQM, KFDA and COFEPRIS.

The company is strategically located in western India with proximity to ports and supplies to beverages, nutraceuticals and pharmaceutical industries worldwide . Its export footprint spans North America, Europe, Asia, and other regions, with shipments to more than 50 countries as mapped in the report . The presentation does not specify the number of subsidiaries.

Aarti Pharmalabs Limited (APL)  Key milestones include:

• 2001: First API unit commissioned at Dombivli (Unit 1); Xanthine unit started.
• 2005: API manufacturing for regulated markets at Tarapur (Unit 4).
• 2008–2019: Multiple regulatory audits/approvals at Tarapur and Vapi, including USFDA, EU GMP, COFEPRIS and EDQM; caffeine production launched at Unit 5 in 2016 (100 MT/month).
• 2022–2023: Demerger completed; third R&D centre operationalised; Dombivli unit secured USFDA approval; Block V at Tarapur Unit 4 commercialised; Xanthine capacity enhanced to 5,000 TPA.

Aarti Pharmalabs Limited (APL)’s Business Segments

Segment mix (Q4FY24): Xanthine Derivatives 44.0%, API & Intermediates 37.6%, CDMO/CMO 18.4%.

Revenue by geography (FY24): International 52%, Domestic 48%.

Aarti Pharmalabs Limited Key Management

• Shri Rashesh C. Gogri, Chairman
• Smt. Hetal Gogri Gala, Vice Chairperson & Managing Director
• Shri Narendra Salvi, Managing Director

Latest Updates on Aarti Pharmalabs Limited (APL) 

• APL expanded capacity in its Custom Synthesis Division (CSD) at Vapi and in API operations at Tarapur, and acquired land at Atali to support future growth. 
• The company is executing ongoing capex at Atali, adding 400+ KL of reactor volume in Phase 1, with commercialisation expected in Q4FY25. APL is also setting up a solar power plant facility, estimated to generate over one-third of its power requirements. Its business focus remains on strengthening APIs and CDMO through value-added products, new customer acquisitions and fortifying its leading position in Xanthine derivatives via brownfield expansion.